Request for Proposals: Efficacy of Lebrikizumab in patients with fibrosing skin conditions
Supports investigator-led research on lebrikizumab’s efficacy in treating fibrosing skin conditions, inviting both pre-clinical and clinical studies managed by the applicant.
Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027 (Full application deadline, projected)
Funding Amounts: Funding and/or study drug support available; typical award size and duration not specified—varies by project scope.
Summary: Supports investigator-initiated research on the efficacy of lebrikizumab in patients with fibrosing skin conditions.
Key Information: This is a forecasted grant; all dates are projected and subject to change.
Description
This opportunity from Eli Lilly and Company supports external research proposals investigating the efficacy of lebrikizumab in patients with fibrosing skin conditions. Researchers are invited to design, initiate, and sponsor studies that address this area of dermatological interest. Approved projects will be fully managed by the grantee, including study design, conduct, and regulatory sponsorship. Proposals are reviewed by Lilly’s global medical and scientific committees, with possible input from external experts.
